Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy

Table 4 Patients with testicular germ cell tumors who underwent cisplatin-based chemotherapy and experienced a thromboembolic event in the literature

Ref.	Number of patients	Percentage of patients with TE	Main findings
Piketty et al[9], 2005	100 patients with GCT; 100 controls with various neoplasms	19 (19%)	> All stages of TGCT;
			> TE: 1st day of chemo to 6 mo after;
			> Of 19 TEE, 14 occurred during chemotherapy, 5 after chemo;
			> Risk factors for TEE: High body surface area, elevated serum LDH
Honecker et al[6], 2013	193	22 (11%)	> All stages of TGCT;
			> TEE: Considered therapy-associated if occurred from start of chemotherapy to 6 wk after;
			> 18 (%) TEE occurred before chemotherapy;
			> Risk factors for TEE: Pure seminoma, retroperitoneal or supraclavicular lymph node metastases, elevated LDH, CVC
Bezan et al[18], 2017	657	34 (5.2%)	> All stages of TGCT;
			> TEE: During 1st year of follow-up;
			> Risk factors for TEE: Higher clinical stage and RPLN, increased number of cycles of chemotherapy
Tran et al[19], 2019	1135	150 (10%)	> Metastatic TGCT;
			> TEE: During or within 90 d of chemotherapy;
			> Risk factors for TEE: Large RPLN, CVC
Paffenholz et al[16], 2019	225	49 (19%)	> All stages of TGCT;
			> TEE: Start of chemotherapy to 6 mo after;
			> Risk factors for TEE: Higher clinical stage, elevated serum LDH, febrile neutropenia, CVC;
			> Patients with TEE had significantly reduced overall survival during median follow-up of 8 mo
Current Study, 2020	68	18 (26.5%)	> All stages of TCGT;
			> TEE: Following orchiectomy;
			> Risk factors for TEE: Higher pathologic stage, greater number of chemotherapy cycles

TGCT: Testicular germ cell tumor; TEE: Thromboembolic event; LDH: Lactic acid dehydrogenase; RPLN: Retroperitoneal lymph node; CVC: Central venous catheter.